AGEN 1884

Drug Profile

AGEN 1884

Alternative Names: AGEN-1884

Latest Information Update: 11 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator 4-Antibody; Ludwig Institute for Cancer Research
  • Developer Agenus; Recepta biopharma
  • Class Antineoplastics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 24 Jul 2017 Agenus plans a phase IIa trial of AGEN 1884 in combination with pembrolizumab for Non Small Cell Lung Cancer (First line therapy, Combination therapy, Metastatic) in Australia and New Zealand in August 2017 (ACTRN12617001061325p)
  • 05 Jun 2017 Interim efficacy and adverse events data from a phase I dose escalation trial in Cancer released by Agenus
  • 02 Jun 2017 Pharmacokinetics data from a phase I trial in Cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top